Tags

Type your tag names separated by a space and hit enter

Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents.
Psychopharmacology (Berl) 1982; 78(2):104-11P

Abstract

The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition). These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg. Generally, the dose-response curves were bell-shaped. The mechanisms underlying the activity of aniracetam and its 'therapeutic window' are unknown. Piracetam, another pyrrolidinone derivative was used for comparison. It was active only in six of nine tests and had about one-tenth the potency of aniracetam. The results indicate that aniracetam improves cognitive functions which are impaired by different procedure and in different phases of the learning and memory process.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

6817363

Citation

Cumin, R, et al. "Effects of the Novel Compound Aniracetam (Ro 13-5057) Upon Impaired Learning and Memory in Rodents." Psychopharmacology, vol. 78, no. 2, 1982, pp. 104-11.
Cumin R, Bandle EF, Gamzu E, et al. Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents. Psychopharmacology (Berl). 1982;78(2):104-11.
Cumin, R., Bandle, E. F., Gamzu, E., & Haefely, W. E. (1982). Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents. Psychopharmacology, 78(2), pp. 104-11.
Cumin R, et al. Effects of the Novel Compound Aniracetam (Ro 13-5057) Upon Impaired Learning and Memory in Rodents. Psychopharmacology (Berl). 1982;78(2):104-11. PubMed PMID: 6817363.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents. AU - Cumin,R, AU - Bandle,E F, AU - Gamzu,E, AU - Haefely,W E, PY - 1982/1/1/pubmed PY - 1982/1/1/medline PY - 1982/1/1/entrez SP - 104 EP - 11 JF - Psychopharmacology JO - Psychopharmacology (Berl.) VL - 78 IS - 2 N2 - The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition). These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg. Generally, the dose-response curves were bell-shaped. The mechanisms underlying the activity of aniracetam and its 'therapeutic window' are unknown. Piracetam, another pyrrolidinone derivative was used for comparison. It was active only in six of nine tests and had about one-tenth the potency of aniracetam. The results indicate that aniracetam improves cognitive functions which are impaired by different procedure and in different phases of the learning and memory process. SN - 0033-3158 UR - https://www.unboundmedicine.com/medline/citation/6817363/Effects_of_the_novel_compound_aniracetam__Ro_13_5057__upon_impaired_learning_and_memory_in_rodents_ L2 - https://medlineplus.gov/memory.html DB - PRIME DP - Unbound Medicine ER -